BRIEF—Teva launches first authorized generic of Victoza in USA

The US affiliate of Teva Pharmaceutical Industries announced today the launch of an authorized generic of Victoza (liraglutide injection 1.8mg), in the USA.

“By launching an authorized generic for Victoza (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, senior vice president, head of US Commercial Generics at Teva.

“In addition to strengthening Teva's diverse complex generics portfolio, we are providing the first generic GLP-1 product to the US marketplace, demonstrating once again our ability to sustain a generics powerhouse,” he added.

Marketed by Danish diabetes care giant Novo Nordisk, Victoza had annual sales of $1.656 billion as of April 2024, Teva revealed in its press release.